Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. The company is headquartered in South San Francisco, California and currently employs 128 full-time employees. The company went IPO on 2020-04-24. The firm is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The firm's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Follow-Up Questions
Oric Pharmaceuticals Inc 'in CEO'su kimdir?
Dr. Jacob Chacko 2018 'den beri şirketle birlikte olan Oric Pharmaceuticals Inc 'in President 'ıdır.
ORIC hissesinin fiyat performansı nasıl?
ORIC 'in mevcut fiyatı $10.56 'dir, son işlem günde 0.04% increased etti.
Oric Pharmaceuticals Inc için ana iş temaları veya sektörler nelerdir?
Oric Pharmaceuticals Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 13 analist Oric Pharmaceuticals Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 9 güçlü al, 8 al, 1 tut, 0 sat ve 9 güçlü sat içermektedir
